InnoVec Pharmaceutical Technology

InnoVec Biotherapeutics is a clinical-stage biotechnology company specializing in the development of next-generation gene therapies using advanced Adeno-Associated Virus (AAV) vector technology. The company focuses on addressing unmet medical needs in ophthalmology and central nervous system (CNS) disorders through its proprietary AAV engineering platform, which optimizes tissue-specific targeting and expression. Its lead program, IVB-102, is a gene therapy designed for the treatment of neovascular age-related macular degeneration and other vascular retinal diseases. Headquartered in Suzhou, China, with additional operations in Shanghai, InnoVec aims to provide long-lasting, single-injection treatments that reduce the burden of frequent intravitreal injections for patients.